TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes~* Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study~* Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10%~Exclusion Criteria:~* Type 1 Diabetes~* Hepatic (liver) impairment~* Renal (kidney) failure or dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dapagliflozin 2.5mg + Glimepiride
- 2 (Type: EXPERIMENTAL): dapagliflozin 5mg + Glimepiride
- 3 (Type: EXPERIMENTAL): dapagliflozin 10mg + Glimepiride
- 4 (Type: PLACEBO_COMPARATOR): Placebo + Glimepiride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females older than 17 years.~2. Clinical diagnosis of Parkinson disease or multiple system atrophy.~3. Provide written informed consent to participate in the study.~4. Understand that they may withdraw their consent at any time.~Exclusion Criteria:~1. Women who are pregnant or lactating.~2. In the investigator's opinion, have significant systemic, hepatic, cardiovascular, renal or other illness that can interfere based on investigator judgment with the trial.~3. History of dementia.~4. Unable to walk without help for at least 1 minute.~5. History of allergic reaction to insulin.~6. The presence of inflammation of nasal cavity that may prevents absorption of insulin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin (Type: EXPERIMENTAL): 40 IU of intranasal insulin daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo arm using intranasal normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged between 17 and 60 years who weigh at least 50kg.~* Pass pre-donation screening using the NBSG standardised donor screening questionnaire for medical conditions and lifestyle risks for transfusion transmissible infections~* Vital signs must meet the NBSG requirement for blood donation: systolic and diastolic blood pressures between 90-140 mmHg and 60- 90 mmHg, respectively; pulse rate between 50-100 bpm; non-contact forehead temperature not exceeding 37.5°C; meeting acceptable requirements for skin lesions, needle marks and physical appearance.~* Must be willing and able to give study consent or assent.~* Intend to remain in the study location/site during the entire length of the study.~Exclusion Criteria:~* Persons who have used iron supplementation within the past one month.~* Participant reports having previously donated blood.~* Evidence for a TTI at baseline among those who successfully donated.~* Evidence of Malaria and helminthic infections at baseline~* Participants who have Hb \<10g/dl at screening

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Iron Supplementation (Type: EXPERIMENTAL): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Bupivacaine/Morphine in Laparoscopic Gastro-intestinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Laparoscopic Gastro-intestinal surgery~Exclusion Criteria:~* Bariatric surgery, gastric surgery, rectal surgery, kidney failure, aorta-valve stenosis, coagulation disorders, emergency surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spinal injection (Type: ACTIVE_COMPARATOR): Patients receive spinal injection Bupivacaine/Morphine
- Subcutaneum injection (Type: PLACEBO_COMPARATOR): Placebo subcutaneum injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Type 1 diabetes and end stage renal disease.~* Women of childbearing potential must have had a negative pregnancy test (serum or urine).~* Patient agrees to participate in the study and sign an informed consent.~* Patient has no known contraindication to the administration of rapamycin or mycophenolate mofetil.~* Patient has no history of hypersensitivity to rapamycin or mycophenolate mofetil.~Exclusion Criteria:~* Patient has history of a malignancy within two years, with the exception of adequately treated localized squamous or basal cell carcinoma of the skin without evidence of recurrence.~* Patient is currently abusing drugs or alcohol.~* Patient is known or suspected to have an active infection or be seropositive for hepatitis B surface antigen (HBsAg), hepatitis C (HCV) or human immunodeficiency virus (HIV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus plus MMF plus Steroids (Type: ACTIVE_COMPARATOR): Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
- Tacrolimus plus Rapamycin plus Steroids (Type: EXPERIMENTAL): Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older.~* Moderate to severe high blood pressure. This is defined as a systolic pressure (the top number) greater than or equal to 160 mmHg and less than 200 mmHg.~Exclusion Criteria:~* History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics~* Inability to stop all prior blood pressure medications safely~* Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg~* Controlled blood pressure (systolic BP \< 140 mmHg) taking more than 3 antihypertensive medications at screening~* Systolic BP ≥ 140 mmHg and \< 180 mmHg taking more than two antihypertensive medications at screening~* Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening~* History of autoimmune diseases~* History of multiple drug allergies~* Liver disease~* Pancreatic injury within 1 year of screening~* Evidence of kidney impairment or history of dialysis~* Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug. This could include currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.~* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, would be excluded UNLESS they are post-menopausal, surgically sterile OR are using acceptable methods of contraception. The use of hormonal contraceptives is not allowed~* Pregnant or nursing (lactating) women~* History of malignancy of any organ system within the past five years~* Any severe, life-threatening disease within the past five years~* History of drug or alcohol abuse within the last 2 years.~* History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack or unstable angina~* Type 1 diabetes~* Poorly controlled Type 2 diabetes~* History of heart failure~* Arrhythmia~* Significant valvular heart disease~* Active gout~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with T2DM aged 19 to 80 years~2. Subjects who have received metformin alone at a fixed dose for the last 8 weeks and has 7% ≤ HbA1c ≤ 10.5%~3. Subjects with BMI of 20-45 kg/m2~4. Subjects who voluntarily decided to participate and provided written consent after being told of the objectives, method, and effects of this study~Exclusion Criteria:~1. Subjects with current or history of hypersensitivity to the IP of this study, metformin or drugs of the same class and their components (e.g., history of hypersensitivity to biguanide or SGLT2 inhibitors)~2. Diabetic ketoacidosis, diabetic coma or precoma within the past year~3. Urinary tract infections or genital infections within~4. Uncontrolled hypertension (SBP \> 180 mmHg or DBP \> 110 mmHg)~5. eGFR \< 60 mL/min/1.73 m2~6. Severe heart failure (NYHA class III/IV)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Study group (Type: EXPERIMENTAL): DWP16001 A mg, Dapagliflozin placebo
- Control group (Type: ACTIVE_COMPARATOR): DWP16001 A mg placebo, Dapagliflozin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Visual Analogue Scale (VAS) of pain is higher than 40 mm.~* Diagnosis of type 1 or 2 diabetes mellitus for at least 1 year~Exclusion Criteria:~* Malignancy within the past 2 years.~* Neurologic disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathy pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin 300 mg/day (Type: EXPERIMENTAL): None
- Pregabalin 600 mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is able to provide written assent and the parents or legal guardian of the patient is able to provide written informed consent before beginning and study related procedures~* Patient has a documented clinical diagnosis of Bipolar I mania~* Patient's parent or legal guardian will be able to accompany the patient at each scheduled study visit~Exclusion Criteria:~* Patients (female) must not be pregnant or lactating~* Patients with a known intolerance or lack of response to previous treatment with quetiapine~* Patients who have previously participated in this study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacist Intervention for Glycemic Control in The Community

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female over 18 years of age~* Type 2 diabetes for at least 6 months~* Taking 1 or more oral hypoglycemic agents~* Patient attending your community pharmacy where you decided that addition of insulin glargine may be of benefit to the patient~* Baseline HbA1c 7.5 - 11%~* Signed informed consent~Exclusion Criteria:~* Have used, or currently using, Insulin~* History of ketoacidosis~* Pregnant~* Works night shift~* Renal impairment(Serum Creatinine: females ≥ 124 mmol/l, males ≥ 133 mmol/l)~* Clinically unstable~* Unwilling/unable to attend follow up visits~* Unlikely to adhere to study procedures (eg. due to cognitive limitations, severe psychiatric disorder or alcoholism)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: OTHER): 10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hypnosis Versus General Anesthesia in Pediatric Surgery: Clinical and Medico-economic Interests

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient hospitalized in infantile ambulatory surgery unit~* Patient whose general state corresponds to the classification of the American Society of Anesthesiologists (ASA) I to III~* Patient among whom the parents or the legal guardian gave their informed consent~* Patient member in a national insurance scheme~Exclusion Criteria:~* Patient presenting a contraindication to general anesthesia~* Patient presenting a contraindication to hypnosis (Chronic Encephalopathy with psychomotor delay, severe cognitive deficit, documented psychiatric disorders)

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1: General anesthesia (Type: ACTIVE_COMPARATOR): General anesthesia
- 2: Hypnosis (Type: EXPERIMENTAL): Hypnosis with local anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of Parkinson's disease with a minimum duration of 1 year~* Presence of visual and/or auditory hallucinations, and/or delusions, occurring during the four weeks prior to study screening~* Psychotic symptoms must have developed after PD diagnosis was established~* Subject must be on stable dose of anti-Parkinson's medication for 1 month prior to Study Day 1 (Baseline) and during the trial~* Subject that has received stereotaxic surgery for subthalamic nucleus deep brain stimulation must be at least 6 months post surgery and the stimulator settings must have been stable for at least 1 month prior to Study Day 1 (Baseline) and must remain stable during the trial~* The subject is willing and able to provide consent~* Caregiver is willing and able to accompany the subject to all visits~Exclusion Criteria:~* Subject has a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder~* Subject has received previous ablative stereotaxic surgery (i.e., pallidotomy and thalamotomy) to treat Parkinson's disease~* Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder~* Subject has had a myocardial infarction in last six months~* Subject has any surgery planned during the screening, treatment or follow-up periods~Patients will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of psychosis severity, delirium, dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all protocol-specified entry criteria).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Pimavanserin tartrate (ACP-103), 10 mg, tablet, once daily by mouth, 6 weeks
- 3 (Type: EXPERIMENTAL): Pimavanserin tartrate (ACP-103), 40 mg, tablet, once daily by mouth, 6 weeks
- 1 (Type: PLACEBO_COMPARATOR): Placebo tablet, once daily by mouth, 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REDUCE - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Informed consent to participate in study.~* Have had a single negative prostate biopsy within 6 months prior to enrollment in study.~* Have a PSA (prostate specific antigen) between 2.5 and 10 if 50-60 years of age; or a PSA between 3.0 and 10 if over age 60.~* Ability and will to participate in study for 4 years.~Exclusion criteria:~* More than one previous negative prostate biopsy.~* History of prostate cancer.~* Previous prostate surgery.~* Inability to urinate requiring the need of a catheter during the previous 2 years.~* Any condition (other than benign prostatic hypertrophy) which may result in urinary symptoms or changes in urine flow rate.~* Cancer within previous 5 years (other than basal or squamous cell cancers of the skin).~* Any unstable serious medical condition.~* Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride (Avodart), testosterone, or drugs that can block the action of male hormones.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
- dustasteride arm (Type: EXPERIMENTAL): Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adult recipients of de novo cadaveric lung transplants 3-18 months prior to enrollment~Exclusion criteria:~* Patients with thrombocytopenia (platelets \<100,000/mm³), with an absolute neutrophil count of \<1,500/mm³ or leucopenia (leucocytes \<3000/mm³), with anemia with Hb \< 8g/dl at time of screening~* Patients with uncontrolled hypercholesterolemia (\> 350 mg/dL; \> 9.1 mmol/L) or hypertriglyceridemia (\> 750 mg/dL; \> 8.5 mmol/L) at time of screening~* Patients with a history of malignancy of any organ system, treated or untreated, during the last five years, whether or not there is evidence of local recurrence or metastases, except squamous or basal cell carcinoma of the skin Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quadruple low level IS regimen (Type: EXPERIMENTAL): quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
- Centre specific triple IS regimen (Type: EXPERIMENTAL): centre specific CNI-based triple drug immunosuppression (IS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete